Medtronic 2015 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2015 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 166

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166

The following are the principal products offered by our CSH division:
Transcatheter Heart Valves (TCVs) Our latest generation TCVs include the CoreValve family of aortic valves. CoreValve,
which is the only TCV system shown to be superior to open-heart surgery, has received U.S. FDA approval for extreme and
high risk patients. Our next-generation recapturable TCV system, CoreValve Evolut R, has received CE Mark approval and
enrollment in the U.S. IDE is complete.
Percutaneous Coronary Intervention (PCI) Our latest generation PCI stent products include our Resolute Integrity drug-
eluting stent systems, which have received U.S. FDA approval, as well as Resolute Onyx drug-eluting stent systems, which have
received CE Mark approval.
Heart Surgery We offer a complete line of surgical valve replacement and repair products for damaged or diseased heart
valves. Our replacement products include both tissue and mechanical valves. We also offer a complete line of blood-handling
products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen
supply, and body temperature during arrested heart surgery. Additionally, we offer surgical ablation systems and positioning
and stabilization technologies.
Aortic & Peripheral Vascular Disease Management (APV)
Our APV division, which includes a portion of the Covidien Peripheral business, is comprised of a comprehensive line of
products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular
disease (PVD). Our products include endovascular stent graft systems, peripheral drug coated balloon, stent and angioplasty
systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart.
The following are the principal products offered by our APV division:
Endovascular Stent Grafts Our products are designed to treat aortic aneurysms in either the abdomen (AAA) or thoracic
(TAA) regions of the aorta. Our product line includes a range of endovascular stent grafts and accessories including the market-
leading Endurant II abdominal stent graft system and the Valiant Captivia thoracic stent graft system.
Peripheral Vascular Intervention (PVI) Our primary PVI products include percutaneous angioplasty balloons including the
IN.PACT family of drug-coated balloons, which have U.S. FDA and CE Mark approval, as well as peripheral stents such as the
Complete SE Vascular Stent and the Assurant Cobalt Iliac Stent and directional atherectomy products such as the TurboHawk
plaque excision system, and other products to support procedures.
MINIMALLY INVASIVE THERAPIES GROUP
Surgical Solutions
Surgical Solutions develops, manufactures, and markets products and therapies to treat diseases and conditions that are
typically, but not exclusively, addressed by surgeons. In addition, we develop, manufacture, and market several unique products
in the emerging fields of minimally invasive gastrointestinal diagnostics, ablation, and interventional lung.
The following are the principal products offered by our Surgical Solutions division:
Surgical Innovations This business includes sales of stapling, vessel sealing, fixation (hernia mechanical devices), mesh,
hardware and surgical instruments, sutures, and electrosurgery products. Key advanced surgical products include: the Tri-Staple
technology platform for endoscopic stapling, including the Endo GIA reloads and reinforced reloads with Tri-Staple technology
and the Endo GIA ultra universal stapler; the iDrive powered stapling systems; the LigaSure vessel sealing system, a
multifunctional laparoscopic instrument for use with the ForceTriad; the Sonicision cordless ultrasonic dissection system;
AbsorbaTack absorbable mesh fixation device for hernia repair; Symbotex composite mesh for surgical laparoscopic and open
ventral hernia repair; and Parietex ProGrip, a selfgripping, biocompatible solution for inguinal hernias.
Early Technologies Our products include ablation products, and interventional lung and gastrointestinal solutions. This
includes the i·Logic System to evaluate lung lesions; the Cool-tip radiofrequency ablation system; the Evident microwave
ablation system; the PillCam SB, a minimally-invasive, swallowed optical endoscopy technology; and the HALO ablation
catheters for treatment of Barrett’s esophagus.
3